Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 9 clinical trials for diffuse large B-cell lymphoma, of which 5 are open and 4 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 1/phase 2 (2 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 5 clinical trials for nasopharyngeal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (2 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 3 are open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 3 are open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and double-hit lymphoma as inclusion criteria, 2 are phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 4 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 3 are open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 3 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 4 clinical trials for hodgkin lymphoma, of which 1 is open and 3 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 4 clinical trials for lymphoma, of which 0 are open and 4 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 4 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 3 clinical trials for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 2 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 3 clinical trials for post-transplant lymphoproliferative disorder, of which 0 are open and 3 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and post-transplant lymphoproliferative disorder as inclusion criteria, 2 are phase 2 (0 open) and 1 is phase 3 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 3 clinical trials for transformed non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and transformed non-hodgkin lymphoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 3 clinical trials for triple-hit lymphoma, of which 2 are open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and triple-hit lymphoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 2 clinical trials for ALK-positive large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and ALK-positive large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 2 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 2 clinical trials for mediastinal large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 2 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 2 are open and 0 are closed. Of the trials that contain Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and anal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma associated with chronic inflammation, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for germinal center B-cell-like diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 3 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for grade 3b follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and grade 3b follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and leiomyosarcoma as inclusion criteria, 1 is phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for lymphoproliferative disorder, of which 0 are open and 1 is closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and lymphoproliferative disorder as inclusion criteria, 1 is phase 1 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 0 are open and 1 is closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and Richter syndrome as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and squamous cell carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [5].

Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive is an inclusion criterion in 1 clinical trial for vulvar/vaginal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive and vulvar/vaginal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].